Form 4: 10x Genomics Director Shehnaaz Suliman Granted 15,357 Restricted Stock Units

10x Genomics, Inc. Director Shehnaaz Suliman was granted 15,357 shares of Class A Common Stock in the form of Restricted Stock Units (RSUs) on June 3, 2025, as reported in a recent SEC Form 4 filing.

Summary

• Shehnaaz Suliman, a Director of 10x Genomics, Inc. (TXG), acquired 15,357 shares of Class A Common Stock.
• The acquisition occurred on June 3, 2025, and was reported via an SEC Form 4 filing.
• These shares were acquired at a price of $0, indicating they are Restricted Stock Units (RSUs).
• Each RSU represents a contingent right to receive one share of Class A Common Stock upon vesting.
• The RSUs will vest in quarterly installments, with 1/4th vesting on each quarterly anniversary measured from May 21, 2025.
• Vesting is contingent upon Ms. Suliman's continued service as a service provider through each vesting date.
• Following this transaction, Ms. Suliman beneficially owns 28,616 shares of Class A Common Stock directly.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While a standard compensation event, it signifies continued alignment of a director's interests with the company's performance through equity incentives.

Positives

• The grant of Restricted Stock Units (RSUs) to a director aligns the director's interests with those of shareholders, incentivizing long-term performance and retention.
• RSUs are a common form of equity compensation, reflecting standard corporate governance practices for executive and director remuneration.

Future Outlook

The granted Restricted Stock Units (RSUs) are subject to a vesting schedule, with 1/4th of the units vesting on each quarterly anniversary measured from May 21, 2025, contingent on the director's continued service. This indicates future share issuances as the RSUs vest.

Industry Context

The grant of Restricted Stock Units (RSUs) to a director is a standard practice in the biotechnology and life sciences industry, including genomics companies like 10x Genomics, to attract, retain, and incentivize key personnel by aligning their compensation with company performance and shareholder value.

Related Party Transactions

• The grant of 15,357 Restricted Stock Units (RSUs) to Shehnaaz Suliman, a Director of 10x Genomics, Inc., constitutes a related party transaction as it involves compensation from the company to a member of its board.

Stakeholder Impact

• Shareholders: The vesting of RSUs will result in a minor dilution of existing shares over time as new shares are issued.
• Employees (specifically the director): The RSU grant provides a significant incentive for the director to remain with the company and contribute to its long-term success, aligning their financial interests with company performance.

Next Steps

• Quarterly vesting of the 15,357 Restricted Stock Units will occur, starting from the quarterly anniversary of May 21, 2025, subject to continued service.

Key Dates

Keywords

10x Genomics, TXG, Restricted Stock Units, RSU, Insider Transaction, SEC Form 4, Director Compensation, Equity Grant, Beneficial Ownership